We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+41.14%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.71B
AUM Growth
-$3.29B
Cap. Flow
-$4.28B
Cap. Flow %
-91.04%
Top 10 Hldgs %
76.49%
Holding
126
New
17
Increased
33
Reduced
15
Closed
22

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$44.9M
2
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$20.1M
3
BPMC
Blueprint Medicines
BPMC
+$19.9M
4
NKTR icon
Nektar Therapeutics
NKTR
+$15.4M
5
AUTL
Autolus Therapeutics
AUTL
+$13.9M

Top Sells

Rank Stock Value
1
BUFF
Blue Buffalo Pet Products, Inc
BUFF
+$3.48B
2
WW
WW International
WW
+$678M
3
INCY icon
Incyte
INCY
+$25M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$19.8M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$13.1M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 44.73%
2 Healthcare 36.09%
3 Communication Services 0%
4 Consumer Staples 0%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
26
CALL
BioMarin Pharmaceuticals
BMRN
$11.9B
$18.8M 0.4%
200,000
– –
ALBO
27
DELISTED
Albireo Pharma Inc
ALBO
$17.8M 0.38%
500,000
-47,841
-9% -$1.55M
FCX icon
28
CALL
Freeport-McMoran
FCX
$86.3B
$17.3M 0.37%
1,000,000
– –
IFRX icon
29
InflaRx
IFRX
$243M
$16.1M 0.34%
500,000
+375,000
+300% +$13M
SAGE
30
DELISTED
Sage Therapeutics
SAGE
$15.7M 0.33%
100,000
– –
KYNB
31
Kyntra Bio
KYNB
$27.7M
$15.7M 0.33%
10,000
– –
TSRO
32
CALL
DELISTED
TESARO, Inc.
TSRO
$15.6M 0.33%
350,000
+200,000
+133% +$9.71M
XNCR icon
33
Xencor
XNCR
$1.45B
$14.8M 0.31%
400,000
+100,000
+33% +$3.45M
MDCO
34
DELISTED
Medicines Co
MDCO
$14.7M 0.31%
400,000
+200,000
+100% +$6.5M
NKTR icon
35
CALL
Nektar Therapeutics
NKTR
$2.39B
$14.6M 0.31%
20,000
+6,667
+50% +$7.69M
ANAB icon
36
AnaptysBio
ANAB
$1.55B
$14.2M 0.3%
200,000
+10,000
+5% +$839K
AUTL
37
Autolus Therapeutics
AUTL
$389M
$14.1M 0.3%
+525,000
New +$13.9M
MDGL icon
38
Madrigal Pharmaceuticals
MDGL
$12.6B
$14M 0.3%
50,000
+5,000
+11% +$878K
BPMC
39
CALL
DELISTED
Blueprint Medicines
BPMC
$12.7M 0.27%
200,000
+150,000
+300% +$11.9M
ARGX icon
40
argenx
ARGX
$55.2B
$12.4M 0.26%
150,000
– –
LRMR icon
41
Larimar Therapeutics
LRMR
$377M
$12.3M 0.26%
100,000
– –
AXDX
42
CALL
DELISTED
Accelerate Diagnostics
AXDX
$11.2M 0.24%
+50,000
New +$11.2M
AXDX
43
DELISTED
Accelerate Diagnostics
AXDX
$11.2M 0.24%
50,000
– –
PRQR icon
44
ProQR Therapeutics
PRQR
$246M
$10.9M 0.23%
1,500,000
-400,000
-21% -$2.02M
RGNX icon
45
Regenxbio
RGNX
$615M
$10.8M 0.23%
150,000
-100,000
-40% -$4.78M
EXEL icon
46
CALL
Exelixis
EXEL
$13.9B
$10.8M 0.23%
+500,000
New +$10.3M
CBAY
47
DELISTED
Cymabay Therapeutics
CBAY
$10.7M 0.23%
800,000
+400,000
+100% +$5.01M
ALNY icon
48
CALL
Alnylam Pharmaceuticals
ALNY
$38.3B
$9.85M 0.21%
+100,000
New +$9.92M
GBT
49
DELISTED
Global Blood Therapeutics, Inc.
GBT
$9.04M 0.19%
200,000
– –
BOLD
50
DELISTED
Audentes Therapeutics, Inc
BOLD
$9.02M 0.19%
236,000
+86,000
+57% +$3.19M
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2018 Portfolio in Review

As of Q2 2018, Artal Group held 126 positions worth $4.71B, down 41% from $7.99B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Artal Group withdrew a net $4.28B in Q2 2018, closing 22 positions and reducing 15 holdings. Its most notable exit was Blue Buffalo Pet Products, Inc, an estimated $3.48B position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 45% of assets, up from 23% a quarter earlier, followed by Healthcare and Communication Services.

Against the trend, Artal Group opened a new position in Scholar Rock worth $37.4M.

  • Artal Group's largest Q2 2018 buy was Scholar Rock: 2,396,040 shares worth $37.4M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q2 2018, an estimated $20.1M increase.
  • Artal Group's biggest Q2 2018 reduction was WW International, cutting an estimated $678M.
  • Artal Group fully exited Blue Buffalo Pet Products, Inc in Q2 2018, selling an estimated $3.48B.
  • Artal Group's ten largest holdings make up 76% of its $4.71B portfolio in Q2 2018.
  • Artal Group opened 17 new positions and closed 22 in Q2 2018.
  • Artal Group's portfolio value fell 41% quarter-over-quarter to $4.71B.

Based on Artal Group's 13F filing for Q2 2018, filed 10 Aug 2018.